Oppenheimer Comments on Agios Pharmaceuticals Inc’s Q1 2019 Earnings (AGIO)

Share on StockTwits

Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Equities researchers at Oppenheimer issued their Q1 2019 earnings estimates for Agios Pharmaceuticals in a report released on Wednesday, February 20th. Oppenheimer analyst L. Cann expects that the biopharmaceutical company will earn ($1.77) per share for the quarter. Oppenheimer currently has a “Market Perform” rating on the stock. Oppenheimer also issued estimates for Agios Pharmaceuticals’ Q2 2019 earnings at ($1.72) EPS and FY2023 earnings at $1.48 EPS.

A number of other research analysts also recently commented on the company. BidaskClub downgraded Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 30th. Piper Jaffray Companies lowered their price objective on Agios Pharmaceuticals to $100.00 and set an “overweight” rating for the company in a research note on Thursday, February 14th. ValuEngine downgraded Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 25th. restated a “hold” rating on shares of Agios Pharmaceuticals in a research note on Friday, November 16th. Finally, Zacks Investment Research downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Agios Pharmaceuticals has a consensus rating of “Buy” and an average target price of $97.86.

Shares of NASDAQ AGIO opened at $57.88 on Thursday. Agios Pharmaceuticals has a twelve month low of $41.63 and a twelve month high of $99.82. The company has a market capitalization of $3.37 billion, a PE ratio of -9.60 and a beta of 2.38.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 14th. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.65) by $0.07. Agios Pharmaceuticals had a negative return on equity of 44.13% and a negative net margin of 366.61%. The business had revenue of $30.00 million during the quarter, compared to the consensus estimate of $19.98 million. During the same period in the previous year, the business earned ($1.81) EPS. The business’s quarterly revenue was up 200.0% on a year-over-year basis.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC grew its stake in Agios Pharmaceuticals by 0.7% during the 3rd quarter. FMR LLC now owns 8,698,886 shares of the biopharmaceutical company’s stock worth $670,858,000 after buying an additional 58,043 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Agios Pharmaceuticals by 2.7% in the third quarter. Vanguard Group Inc now owns 4,251,439 shares of the biopharmaceutical company’s stock worth $327,871,000 after purchasing an additional 109,849 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Agios Pharmaceuticals by 2.7% in the third quarter. Vanguard Group Inc. now owns 4,251,439 shares of the biopharmaceutical company’s stock worth $327,871,000 after purchasing an additional 109,849 shares in the last quarter. BlackRock Inc. grew its stake in shares of Agios Pharmaceuticals by 1.2% in the fourth quarter. BlackRock Inc. now owns 3,324,479 shares of the biopharmaceutical company’s stock worth $153,292,000 after purchasing an additional 38,637 shares in the last quarter. Finally, Capital International Investors grew its stake in shares of Agios Pharmaceuticals by 10.4% in the third quarter. Capital International Investors now owns 3,096,422 shares of the biopharmaceutical company’s stock worth $238,796,000 after purchasing an additional 291,393 shares in the last quarter. Hedge funds and other institutional investors own 97.86% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Further Reading: Do back-end load funds outperform no-load funds?

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.